---
document_datetime: 2023-09-21 18:03:22
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/tafinlar-epar-all-authorised-presentations_en.pdf
document_name: tafinlar-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 1.2841648
conversion_datetime: 2025-12-19 03:38:34.214768
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Annex A

<div style=\"page-break-after: always\"></div>

| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form   | Route of   | Immediate Packaging   | Pack size    |
|------------------|-------------------|------------|-----------------------|------------|-----------------------|--------------|
| EU/1/13/865/001  | Tafinlar          | 50 mg      | Capsule, hard         | Oral use   | bottle (HDPE)         | 28 capsules  |
| EU/1/13/865/002  | Tafinlar          | 50 mg      | Capsule, hard         | Oral use   | bottle (HDPE)         | 120 capsules |
| EU/1/13/865/003  | Tafinlar          | 75 mg      | Capsule, hard         | Oral use   | bottle (HDPE)         | 28 capsules  |
| EU/1/13/865/004  | Tafinlar          | 75 mg      | Capsule, hard         | Oral use   | bottle (HDPE)         | 120 capsules |